July 27, 2018
Mayo Clinic in the News Weekly Highlights for July 27, 2018
STAT, Experimental Alzheimer’s drug significantly slowed patients’ cognitive decline, buoying hopes for treatment by Damian Garde — The Phase 2 trial, which employed multiple statistical measures, failed its primary goal. Four doses of BAN2401 didn’t outperform placebo, and the high dose was tested on just 161 patients. Furthermore, the metric Biogen and Eisai used to […]
Tags: alzheimer's disease, amgen, anesthesia, Big Blue Dragon Boat Race, bioethics, brain freeze, BRCA gene, Cancer, dementia, Dr. Amaal Starling, Dr. Amit Sood, Dr. Asad Javed.
February 9, 2012
FDA panel votes against Xgeva for prostate cancer
panel of cancer experts voted against a new use for Amgen’s Xgeva in prostate cancer on Wednesday, saying the drug’s ability to slow the spread of the disease did not translate into meaningful benefits for patients.The Food and Drug Administration’s cancer drug panel voted 12-1 that the benefits of the drug did not outweigh its […]
Tags: amgen, cancer drug panel, Dr. Ronald Richardson, FDA, Food and Drug Administration, prostate cancer, Xgeva